Skip to content

Study · Randomized controlled trial · n = 183 · 1998

2 results

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.

Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, Silani V, Vos PE, Wokke JH, Dobbins T

Neurology1 Aug 1998Cited by 240 (Europe PMC)

PMID9710040 (opens in a new tab)DOI10.1212/wnl.51.2.583 (opens in a new tab)PepBankPUB-09710040
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In ALS patients, rhIGF-I did not significantly change Appel ALS rating scale progression versus placebo.

    In plain wordsIn ALS patients, disease progression did not differ significantly between rhIGF-I and placebo.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeAppel ALS rating scale progression
    Study

    n = 183

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    0.1 mg/kg/day · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups.
    1 context sentence
    Summary · context
    To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months.
  2. 02HumanRandomized controlled trialSafety outcome

    In ALS patients, rhIGF-I appeared safe and well tolerated.

    In plain wordsIn ALS patients, rhIGF-I appeared safe and well tolerated.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    Not applicableSafety and tolerability
    Study

    n = 124

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.1 mg/kg/day · subcutaneous · 9 monthsAs given in this study (human).

    Source sentences

    Summary
    RhIGF-I appeared to be safe and well-tolerated.
    1 context sentence
    Summary · context
    To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.